108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
通过 A549 所分泌的外泌体筛选与肺癌细胞吉西他滨耐药相关的 miRNA
Authors Liang AL, Du SL, Zhang B, Zhang J, Ma X, Wu CY, Liu YJ
Received 18 March 2019
Accepted for publication 23 May 2019
Published 8 July 2019 Volume 2019:11 Pages 6311—6321
DOI https://doi.org/10.2147/CMAR.S209149
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
目的：建立耐吉西他滨的耐药细胞株 A549/G+，并通过普通株 A549 及耐药株 A549/G+ 所分泌的外泌体，筛选差异表达的 miRNAs。
方法：将 A549 细胞在含有吉西他滨的培养基中诱导培养，直至细胞对吉西他滨产生耐药。接着提取 A549 及 A549/G+ 所分泌的外泌体，通过 miRNA 基因芯片对外泌体所含 miRNAs 进行分析。
结果：经过 39 周的连续诱导培养，A549 对吉西他滨产生耐药性，耐药指数达到 6。通过 GeneChip miRNA 4.0 分析，A549 和 A549/G+ 之间存在 446 个差异 miRNA。同时通过靶基因预测及通路分析，找到在调控中具有共同作用的 miRNA，这些 miRNA 很有可能参与了耐药过程。
结论：这些差异 miRNA 有助于深入研究非小细胞肺癌对吉西他滨产生耐药的机制。
Keywords: non-small cell lung cancer, NSCLC, exosomes, miRNA, microarray, drug resistance, gemcitabine
